TBH you can’t throw ARDS away CoVid or non-Covid without...

TBH you can’t throw ARDS away CoVid or non-Covid without examining the dataset. The demographic of patients prescribed REM-L for COVID-19 ARDs in the later participants were older failed with convalescent plasma and other experimental Tx. It’s pretty clear from the DREAM-HF trial that the earlier the cells are delivered the better the response. Less damage to heart lung & brain tissue The shadow of long Covid will be with us for some time. Remember ARDS from influenza, bacterial sepsis and viral infection kills >50k annually in the US alone. Novartis didn’t sign up just to kick the tyres and look at the IP.